Breaking

Multiple French prisons attacked in response to government’s narco crackdown, ministers say
Israeli ministers accuse embattled security agency chief of waging political vendetta against government
Four Russian journalists linked to late Kremlin critic Navalny sentenced at Moscow court
France expels 12 Algerian officials in tit-for-tat move amid diplomatic tensions
Israeli fighter jet drops bomb near Israeli community on Gaza border after “technical malfunction,” IDF says
Peru’s former first lady seeks asylum in Brazilian Embassy as she and ex-President Humala sentenced to prison
Ecuador ‘would love to have US forces’ helping in gang crackdown, president says
Can Africa’s EV revolution support rural women?

World News
Science
Investing
Business
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

WESTERN COPPER AND GOLD STRENGTHENS STRATEGIC PARTNERSHIP WITH MITSUBISHI MATERIALS

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Mali Shuts Barrick Gold’s Office in Bamako Amid Ongoing Tax Dispute

Fill Out & Get More Relevant News

Your name

Your email

Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.
Categories
- Business (1,016)
- Investing (2,349)
- Science (573)
- World News (2,858)

Disclaimer: digitaltradecenter.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest Posts
- Privacy Policy
- Terms & Conditions

Copyright © 2025 digitaltradecenter.com | All Rights Reserved

Top

World News
Science
Investing
Business

Type above and press Enter to search. Press Esc to cancel.